Last reviewed · How we verify
GT90001
At a glance
| Generic name | GT90001 |
|---|---|
| Also known as | PF-03446962 |
| Sponsor | Suzhou Kintor Pharmaceutical Inc, |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma (PHASE2)
- Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) (PHASE1, PHASE2)
- A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GT90001 CI brief — competitive landscape report
- GT90001 updates RSS · CI watch RSS
- Suzhou Kintor Pharmaceutical Inc, portfolio CI